ホーム > 大越 靖/ Okoshi, Yasushi

大越 靖

ALUMNI 2025年4月現在、筑波大学が主たる所属機関ではありません

Okoshi, Yasushi

医学医療系 , 准教授
Faculty of Medicine , Associate Professor

関連記事はまだありません。

オープンアクセス版の論文は「つくばリポジトリ」で読むことができます。
  1. 1. Endogenous reference RNAs for microRNA quantitation in formalin-fixed, paraffin-embedded lymph node tissue Katsushige Inada; Yasushi Okoshi; Yukiko Cho-Isoda; Shingo Ishiguro (+7 著者) Hiroshi Kojima
      Scientific Reports 8: 5918 (2018) Semantic Scholar
  2. 2. Central Nervous System Lymphoma Harboring the JAK2 V617F Mutation that Developed after a 20-year History of Polycythemia Vera Kajikawa, Natsuki; Seki, Yoshimoto; Fujio, Takayuki; Okoshi, Yasushi (+3 著者) Kojima, Hiroshi
      Internal medicine (Tokyo, Japan) 57: 3293 (2018) Semantic Scholar
  3. 3. A single institutional retrospective evaluation for younger patients with primary central nervous lymphomas on a modified R-MPV regimen followed by radiotherapy and high dose cytarabine. Keiichiro Hattori; Mamiko Sakata-Yanagimoto; Yasushi Okoshi; Takayasu Kato (+8 著者) Shigeru Chiba
      Journal of clinical and experimental hematopathology : JCEH 57: 41 (2017) Semantic Scholar
  4. 4. A single institutional retrospective evaluation for younger patients with primary central nervous lymphomas on a modified R-MPV regimen followed by radiotherapy and high dose cytarabine Hattori, Keiichiro; Sakata-Yanagimoto, Mamiko; Okoshi, Yasushi; Kato, Takayasu (+8 著者) Chiba, Shigeru
      Journal of Clinical and Experimental Hematopathology 57: 41 (2017) Semantic Scholar
  5. 5. MYD88 (L265P) mutation is associated with an unfavourable outcome of primary central nervous system lymphoma Hattori, Keiichiro; Sakata-Yanagimoto, Mamiko; Okoshi, Yasushi; Goshima, Yuki (+8 著者) Chiba, Shigeru
      British journal of haematology 177: 492 (2017) Semantic Scholar
  6. 6. MYD88 (L265P) mutation is associated with an unfavourable outcome of primary central nervous system lymphoma Keiichiro Hattori; Mamiko Sakata-Yanagimoto; Yasushi Okoshi; Yuki Goshima (+8 著者) Shigeru Chiba
      British Journal of Haematology 177: 492 (2017) Semantic Scholar
  7. 7. 茨城県合同輸血療法委員会発足後5年間の活動 谷川, 道浩; 山口, 恭子; 大江, 和紀; 羽石, 靖浩 (+21 著者) 大越, 靖
      Japanese Journal of Transfusion and Cell Therapy 63: 630 (2017) Semantic Scholar
  8. 8. First-line treatment and outcome of elderly patients with primary central nervous system lymphoma (PCNSL)-a systematic review and individual patient data meta-analysis B. Kasenda; A. J. M. Ferreri; E. Marturano; D. Forst (+20 著者) M. Briel
      ANNALS OF ONCOLOGY 26: 1305 (2015) Semantic Scholar
  9. 9. Measurement of Proteasome Activity in Peripheral Blood Mononuclear Cells as an Indicator of Susceptibility to Bortezomib-Induced Severe Neurological Adverse Events in Patients with Multiple Myeloma Yukiko Cho; Mitsuo Hori; Yasushi Okoshi; Fumie Fujisawa (+11 著者) Hiroshi Kojima
      ACTA HAEMATOLOGICA 134: 25 (2015) Semantic Scholar
  10. 10. Prognosis Factors in Japanese Elderly Patients with Primary Central Nervous System Lymphoma Treated with a Nonradiation, Intermediate-Dose Methotrexate-Containing Regimen Suk-young Lee; Yasushi Okoshi; Naoki Kurita; Masanori Seki (+3 著者) Shigeru Chiba
      ONCOLOGY RESEARCH AND TREATMENT 37: 378 (2014) Semantic Scholar
  11. 11. Post-transplant gastric antral vascular ectasia after intra-venous busulfan regimen Kuniyoshi Fukuda; Naoki Kurita; Tatsuhiro Sakamoto; Hidekazu Nishikii (+2 著者) Shigeru Chiba
      International Journal of Hematology 98: 135 (2013) Semantic Scholar
  12. 12. Soluble Recombinant Thrombomodulin Is a Potentially Promising Agent without Causing Severe Hemorrhagic Events for Hematological Malignancy-Induced Disseminated Intravascular Coagulation Kurita, Naoki; Nishikii, Hidekazu; Yokoyama, Yasuhisa; Sakata-Yanagimoto, Mamiko (+4 著者) Chiba, Shigeru
      BLOOD 120: (2012)
  13. 13. First-Line Treatment and Outcome of Elderly Patients with Primary Central Nervous System Lymphoma (PCNSL) - A Systematic Review and Individual Patient Data Meta-Analysis Kasenda, Benjamin; Ferreri, Andres J. M; Maturano, Emerenziana; Bromberg (+16 著者) Briel, Matthias
      BLOOD 120: (2012)
  14. 14. Nine years interval between first and second bone marrow transplantations and subsequent long-term survival-a case of acute myeloid leukemia with MLL-AF6 fusion gene Yasuhisa Yokoyama; Kazumi Suzukawa; Yasushi Okoshi; Toru Nanmoku (+3 著者) Shigeru Chiba
      ANNALS OF HEMATOLOGY 91: 1491 (2012) Semantic Scholar
  15. 15. Apoptotic cells suppress mast cell inflammatory responses via the CD300a immunoreceptor Chigusa Nakahashi-Oda; Satoko Tahara-Hanaoka; Masamichi Shoji; Yasushi Okoshi (+7 著者) Akira Shibuya
      JOURNAL OF EXPERIMENTAL MEDICINE 209: 1493 (2012) Semantic Scholar
  16. 16. Isolated Cardiac Involvement of B-Cell Acute Lymphoblastic Leukemia Mimicking Acute Myocardial Infarction With Persistent Broad ST-Segment Elevationc Yuki Kakefuda; Akira Sato; Tomoya Hoshi; Tomoko Ishizu (+6 著者) Kazutaka Aonuma
      CIRCULATION 125: E979 (2012) Semantic Scholar
  17. 17. A lower starting dose of eltrombopag is efficacious in Japanese patients with previously treated chronic immune thrombocytopenia Y. Tomiyama; Y. Miyakawa; S. Okamoto; S. Katsutani (+9 著者) Y. Kanakura
      JOURNAL OF THROMBOSIS AND HAEMOSTASIS 10: 799 (2012) Semantic Scholar
  18. 18. Adverse Effects of Morphine and Fentanyl for Stomatitis in Patients Receiving Allogeneic Hematopoietic Cell Transplantation—A Single Center Retrospective Analysis Okoshi,Yasushi
      Open Journal of Blood Diseases (2012)
  19. 19. HLA-C Matching Status Does Not Affect Rituximab-Mediated Antibody-Dependent Cellular Cytotoxicity by Allogeneic Natural Killer Cells Machino, T; Okoshi, Y; Miyake, Y; Akatsuka, YChiba, S
      Immunological Investigation (2012)
  20. 20. Treatment Outcome of Adult Burkitt Lymphoma in Japanese Patients with Modified LMB Protocol : A Single Center Retrospective Analysis NISHIKII, Hidekazu; NAKAMURA, Naoya; KONDO, Yuzuru; OKOSHI, Yasushi (+7 著者) CHIBA, Shigeru
      Journal of Clinical and Experimental Hematopathology 51: 109 (2011) Semantic Scholar
1 2 3
  1. 1. 分子レベルからみたT/NK細胞分化 大越, 靖; 渋谷, 彰 (担当:監修)
    血液・腫瘍科 2005年8月
  2. 2. Requirement of the tyrosines at residues 258 and 270 of MAIR-I in inhibitory effect on degranulation from basophilic leukemia RBL-2H3. 大越, 靖
    2005年3月
  3. 3. ペアレセプターMAIR-I・MAIR-IIによる骨髄球系細胞の活性化制御機構 大越, 靖; 中橋, ちぐさ; 渋谷, 彰 (担当:監修)
    Molecular Medicine 臨時増刊号 免疫2005 2004年1月
  4. 4. MAIRファミリー分子と正と負の自然免疫制御 大越, 靖; 四本, 克己; 渋谷, 彰 (担当:監修)
    Annual Review 免疫 2004 2003年1月
  5. 5. KIR (Killer cell Immunoglobulin-like receptors) 大越, 靖; 渋谷, 彰 (担当:監修)
    分子細胞治療、第2号 2003年1月
  6. 6. Treatment of PNH hemolytic crisis with heparin or low-molecular weight heparin by its dual (anti-complement and anti-coagulant) activity. Yoshida, C; Okoshi, Y; Hasegawa, Y; Nagasawa, T; Ninomiya, H (担当:監修)
    Paroxymal Nocturial Hemoglobulinemia and Related Disorders 2003年1月
  7. 7. 骨髄球系細胞の活性化制御を担う新しいpaired receptor; MAIR 四本, 克己; 大越, 靖; 渋谷, 彰 (担当:監修)
    Molecular Medicine 臨時増刊号 2002年1月

 597 total views